Meet ESE's new Corporate Members

March 2021

Alexion, Chiasma and Soleno Therapeutics have joined ESE as new Corporate Members or Supporters

ESE welcomes these additions in its engagement with industry partners. Corporate Membership is linked to a number of benefits related to the annual congress, educational initiatives and many other forms of engagement with ESE. Learn more about these companies below.


Chiasma Inc (US) - new Corporate Member
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercialising oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients, who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analogue approved by the FDA, is available for commercial sale in the US. 

Find out more at

Alexion (Switzerland) - new Corporate Member
Alexion is a global biopharmaceutical company focusing on rare diseases. As the global leader in complement biology and inhibition, Alexion commercializes two complement inhibitors to treat patients with paroxysmal nocturnal haemoglobinuria (PNH) as well as atypical haemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent.

Find out more at


Soleno Therapeutics, Inc. (US) - new Corporate Supporter
Soleno Tx is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.

Find out more at